Home » Stocks » Flexion Therapeutics

Flexion Therapeutics, Inc. (FLXN)

Stock Price: $12.26 USD -0.20 (-1.61%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 604.40M
Revenue (ttm) 81.02M
Net Income (ttm) -141.17M
Shares Out 49.30M
EPS (ttm) -3.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $12.26
Previous Close $12.46
Change ($) -0.20
Change (%) -1.61%
Day's Open 12.50
Day's Range 12.22 - 12.61
Day's Volume 308,120
52-Week Range 5.01 - 22.98

More Stats

Market Cap 604.40M
Enterprise Value 630.46M
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 49.30M
Float 44.10M
EPS (basic) -3.58
EPS (diluted) -3.58
FCF / Share -2.98
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 10.07M
Short Ratio 18.18
Short % of Float 27.98%
Beta 2.06
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 7.46
PB Ratio 87.97
Revenue 81.02M
Operating Income -123.60M
Net Income -141.17M
Free Cash Flow -127.37M
Net Cash -26.06M
Net Cash / Share -0.53
Gross Margin 77.76%
Operating Margin -152.56%
Profit Margin -174.20%
FCF Margin -157.21%
ROA -30.64%
ROE -486.91%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 11
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$21.27*
(73.49% upside)
Low
17.0
Current: $12.26
High
35.0
Target: 21.27
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue72.9622.520.36------
Revenue Growth223.91%6244.79%-------
Gross Profit63.0015.190.35------
Operating Income-136-159-130-69.78-46.06-26.99-17.77-15.01-11.29
Net Income-150-170-137-71.89-46.32-27.31-18.19-14.98-11.45
Shares Outstanding38.0937.7533.0325.3021.5013.890.790.540.49
Earnings Per Share-3.93-4.49-4.16-2.84-2.15-1.97-23.02-27.58-23.26
Operating Cash Flow-149-160-108-62.47-38.95-23.14-16.19-13.98-10.35
Capital Expenditures-3.89-0.85-2.15-8.44-5.20-0.80-0.41-0.03-0.04
Free Cash Flow-153-161-110-70.91-44.15-23.95-16.59-14.01-10.39
Cash & Equivalents13725939320611115216.5729.4110.57
Total Debt20315816030.5315.003.565.05--
Net Cash / Debt-65.8910023317696.3214811.5229.4110.57
Assets21829644122612715318.7830.0110.94
Liabilities23818618139.2323.158.418.672.721.78
Book Value-20.11110260187104145-64.70-47.52-32.68
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Flexion Therapeutics, Inc.
Country United States
Employees 288
CEO Michael D. Clayman

Stock Information

Ticker Symbol FLXN
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: FLXN
IPO Date February 12, 2014

Description

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201 a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.